Posted by Michael Wonder on 28 Jun 2024
Pfizer and BioNTech receive positive CHMP opinion for omicron JN.1 adapted COVID-19 Vaccine in the European Union
27 June 2024 - The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older.
Pfizer and BioNTech today announced that the CHMP of the EMA has recommended marketing authorisation for the companies’ Omicron JN.1 adapted monovalent COVID-19 vaccine (Comirnaty JN.1) for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
